Further research is required to determine the optimal treatment sequence for CDK4/6 inhibitors in advanced HR+, HER2− breast cancer, particularly since current data in the second-line setting are from patients who have received no prior CDK4/6 inhibitor-based therapy. Here, CDK4 is linked to breast cancer.